Learn About Oculocutaneous Albinism Type 1

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Oculocutaneous Albinism Type 1 Local Doctors?
BB
Dr. Brian P. Brooks
Ophthalmology
Elite
Highly rated in
21
conditions
Ophthalmology

Childrens National Medical Center

111 Michigan Ave Nw 
Washington, DC 20010

Brian Brooks is an Ophthalmologist in Washington, Washington, D.c.. Dr. Brooks is rated as an Elite doctor by MediFind in the treatment of Oculocutaneous Albinism Type 1. He is also highly rated in 21 other conditions, according to our data. His top areas of expertise are Coloboma, Coloboma of Iris, Ocular Albinism, and Albinism. He is licensed to treat patients in District of Columbia.

View Profile
KO
Ken Okamura
Elite
Highly rated in
17
conditions

Yamagata University Faculty Of Medicine

Yamagata, JP 

Ken Okamura is in Yamagata, Japan. Okamura is rated as an Elite expert by MediFind in the treatment of Oculocutaneous Albinism Type 1. He is also highly rated in 17 other conditions, according to our data. His top areas of expertise are Albinism, Hermansky-Pudlak Syndrome, Oculocutaneous Albinism, and Oculocutaneous Albinism Type 2.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
AW
Aihua Wei
Distinguished
Highly rated in
9
conditions

Beijing Tongren Hospital, Capital Medical University

Beijing, CN 10073

Aihua Wei is in Beijing, China. Wei is rated as a Distinguished expert by MediFind in the treatment of Oculocutaneous Albinism Type 1. They are also highly rated in 9 other conditions, according to our data. Their top areas of expertise are Albinism, Platelet Storage Pool Deficiency, Hermansky-Pudlak Syndrome, and Oculocutaneous Albinism.

View Profile
View All Doctors
What are the Latest Advances for Oculocutaneous Albinism Type 1?
Method of surgical treatment of patients with oculocutaneous albinism using artificial iris.
Condition: Oculocutaneous Albinism
Journal: Vestnik oftalmologii
Treatment Used: Artificial Irises
Number of Patients: 2
Published: March 02, 2022
View publication
Summary: Method of surgical treatment of patients with oculocutaneous albinism using artificial iris.
The Phenotypic and Mutational Spectrum of the FHONDA Syndrome and Oculocutaneous Albinism: Similarities and Differences.
Journal: Investigative ophthalmology & visual science
Published: January 14, 2022
View publication
Summary: The Phenotypic and Mutational Spectrum of the FHONDA Syndrome and Oculocutaneous Albinism: Similarities and Differences.
Tired of the same old research?
Check Latest Advances
Novel deletion of exon 3 in TYR gene causing Oculocutaneous albinism 1B in an Indian family along with intellectual disability associated with chromosomal copy number variations.
Journal: BMC medical genomics
Published: January 04, 2022
View publication
Summary: Novel deletion of exon 3 in TYR gene causing Oculocutaneous albinism 1B in an Indian family along with intellectual disability associated with chromosomal copy number variations.
View All Latest Advances
What are the latest Oculocutaneous Albinism Type 1 Clinical Trials?
Pirfenidone in the Treatment of Hermansky Pudlak Syndrome (HPS) - Related Interstitial Lung Disease (ILD)
Status: Not yet recruiting
Start Date: December 1, 2019
Intervention Type: Drug
Study Drugs: Pirfenidone
Phase: Phase 2
View Trial
Summary: This research study will explore the safety and efficacy of the drug, pirfenidone, in patients with a diagnosis of Hermansky-Pudlak Syndrome (HPS) who have an associated interstitial lung disease (ILD) over a planned period of 56 weeks.
Match to trials
Find the right clinical trials for you in under a minute
Get started
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Status: Recruiting
Start Date: November 6, 1995
View Trial
Summary: Hermansky-Pudlak Syndrome (HPS) is an inherited disease which results in decreased pigmentation (oculocutaneous albinism), bleeding problems due to a platelet abnormality (platelet storage pool defect), and storage of an abnormal fat-protein compound (lysosomal accumulation of ceroid lipofuscin).~The disease can cause poor functioning of the lungs, intestine, kidneys, or heart. The major complicat...
View All Clinical Trials